Biotech Values

[genisi]

Yes it's early, the study is small and only looked at Japanese population and further prospective studies are needed. There's no reason to think that IL28B polymorphisms influence the response to telaprevir alone and not other direct antiviral agents. I see that VRUS is looking at IL28B genotype in this PSI-7977 HCV trial and perhaps others will perform retrospective genotype analysis:

http://clinicaltrials.gov/ct2/show/NCT01054729

Btw, it is not yet known how response to IFN sparing STAT-C combo regimens is linked to IL28 polymorphism but it is also very interesting and will probably be studied.